Pipeline

Pipeline

Our product pipeline currently has four programs that have been developed using our proprietary technology. Three of which are approaching Clinical Candidate status, while the fourth is near the Lead Optimization stage.

Program Lead Identification Lead Optimization Preclinical Development
NUC-1010 LTP-enabled Nucleotide Analog for Hepatitis B Lead Identification Phase complete
Lead Optimization Phase complete
Preclinical Development Phase in progress
NUC-2020 LTP-enabled Agent for Hepatocellular Carcinoma Lead Identification Phase complete
Lead Optimization Phase in progress
Preclinical Development Phase not started
NUC-3030 LTP-enabled Agent for Solid Tumor Lead Identification Phase complete
Lead Optimization Phase in progress
Preclinical Development Phase not started